Avalon Pharma profit up 21% to SAR 79.9M in 2024; Q4 at SAR 44.8M

Avalon Pharma profit up 21% to SAR 79.9M in 2024; Q4 at SAR 44.8M

23/03/2025 Argaam Exclusive

View other reports

Middle East Pharmaceutical Industries Co. (Avalon Pharma) posted a net profit of SAR 79.9 million for 2024, a rise of 21% from SAR 65.8 million a year earlier.



Financials (M)

Item 2023 2024 Change‬
Revenues 338.44 394.00 16.4 %
Gross Income 204.02 243.36 19.3 %
Operating Income 78.25 91.03 16.3 %
Net Income 65.83 79.85 21.3 %
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items 3.29 3.99 21.3 %
EPS (Riyals) 3.29 3.99 21.3 %


Current Quarter Comparison (M)

Compared With The
Item Q4 2023 Q4 2024 Change‬
Revenues 129.17 135.99 5.3 %
Gross Income 83.39 85.79 2.9 %
Operating Income 48.65 47.24 (2.9 %)
Net Income 45.41 44.81 (1.3 %)
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items 2.27 2.24 (1.3 %)
EPS (Riyals) 2.27 2.24 (1.3 %)

View More Financial Results

 

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.